International consensus on (ICON) anaphylaxis

Simple item page
dc.contributor.authorSimons, F Estelle R
dc.contributor.authorArdusso, Ledit RF
dc.contributor.authorBilò, M B
dc.contributor.authorCardona, Victoria
dc.contributor.authorEbisawa, Motohiro
dc.contributor.authorEl-Gamal, Yehia M
dc.contributor.authorLieberman, Phil
dc.contributor.authorLockey, Richard F
dc.contributor.authorMuraro, Antonella
dc.contributor.authorRoberts, Graham
dc.contributor.authorSanchez-Borges, Mario
dc.contributor.authorSheikh, Aziz
dc.contributor.authorShek, Lynette P
dc.contributor.authorWallace, Dana V
dc.contributor.authorWorm, Margitta
dc.date.accessioned2014-05-30T11:11:07Z
dc.date.available2014-05-30T11:11:07Z
dc.date.issued2014-05-30
dc.date.updated2014-05-30T11:11:08Z
dc.description.abstractAbstract ICON: Anaphylaxis provides a unique perspective on the principal evidence-based anaphylaxis guidelines developed and published independently from 2010 through 2014 by four allergy/immunology organizations. These guidelines concur with regard to the clinical features that indicate a likely diagnosis of anaphylaxis -- a life-threatening generalized or systemic allergic or hypersensitivity reaction.They also concur about prompt initial treatment with intramuscular injection of epinephrine (adrenaline) in the mid-outer thigh, positioning the patient supine (semi-reclining if dyspneic or vomiting), calling for help, and when indicated, providing supplemental oxygen, intravenous fluid resuscitation and cardiopulmonary resuscitation, along with concomitant monitoring of vital signs and oxygenation. Additionally, they concur that H1-antihistamines, H2-antihistamines, and glucocorticoids are not initial medications of choice.For self-management of patients at risk of anaphylaxis in community settings, they recommend carrying epinephrine auto-injectors and personalized emergency action plans, as well as follow-up with a physician (ideally an allergy/immunology specialist) to help prevent anaphylaxis recurrences.ICON: Anaphylaxis describes unmet needs in anaphylaxis, noting that although epinephrine in 1 mg/mL ampules is available worldwide, other essentials, including supplemental oxygen, intravenous fluid resuscitation, and epinephrine auto-injectors are not universally available.ICON: Anaphylaxis proposes a comprehensive international research agenda that calls for additional prospective studies of anaphylaxis epidemiology, patient risk factors and co-factors, triggers, clinical criteria for diagnosis, randomized controlled trials of therapeutic interventions, and measures to prevent anaphylaxis recurrences. It also calls for facilitation of global collaborations in anaphylaxis research.In addition to confirming the alignment of major anaphylaxis guidelines, ICON: Anaphylaxis adds value by including summary tables and citing 130 key references. It is published as an information resource about anaphylaxis for worldwide use by healthcare professionals, academics, policy-makers, patients, caregivers, and the public.
dc.description.versionPeer Reviewed
dc.identifier.citationWorld Allergy Organization Journal. 2014 May 30;7(1):9
dc.identifier.doihttp://dx.doi.org/10.1186/1939-4551-7-9
dc.identifier.urihttp://hdl.handle.net/1993/23609
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderF Estelle R Simons et al.; licensee BioMed Central Ltd.
dc.titleInternational consensus on (ICON) anaphylaxis
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
1939-4551-7-9.xml
Size:
232.52 KB
Format:
Extensible Markup Language
Description:
Download
Thumbnail Image
Name:
1939-4551-7-9.pdf
Size:
927.39 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.17 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works